

Remarks


By way of this Preliminary Amendment, claims 1-21 are pending. Claims 4, 7, 8, 14, and 21 have been amended. These claim amendments are being made solely for purposes of placing the claims in a format appropriate for U.S. prosecution. Applicants submit that the amendments do not change the scope of the claims as originally filed. Such amendments are therefore made to address formalities in the claim format and are not related to the patentability of the subject matter of the claims. No new matter was added by way of these claim amendments and additions.

Conclusion

Applicants believe that the subject matter of the pending claims is patentable and that the instant application should accordingly be allowed. If the Examiner believes that a conversation with Applicants' attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned attorney at (203) 812-6450.

Respectfully submitted,

Dated: March 16, 2006

  
\_\_\_\_\_  
Susan M. Pellegrino  
Attorney for Applicants  
Reg. No. 48,972

Bayer Pharmaceuticals Corporation  
400 Morgan Lane  
West Haven, CT 06516  
(Tel) (203) 812-6450  
(Fax) (203) 812-6459